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Abstract 
Two high-affinity DNA aptamers for lung tumor cells were applied as biospecific elements in 
bioluminescent assay of patient blood. The oligonucleotide complementary to the 5' end of 
both aptamers carrying either biotin or Ca2+-regulated photoprotein obelin was used to form a 
sandwich-type analytical complex on the surfaces of magnetic streptavidin-activated 
microspheric particles. Clinical blood samples from cases of morphologically confirmed lung 
cancer and control samples were analyzed applying the developed assay. From the receiver-
operator curve (ROC) analysis, the chosen threshold value as clinical decision limit offers 
sensitivity of 91.5% and specificity of 75% (p<0.001). The area under ROC curve (AUC) 
with the value of 0.901 distinguishes well between the two groups under investigation. 
 
1. Introduction 
Analytical technologies, both in vitro and in vivo, based on light-emitting (bioluminescent) 
proteins – luciferases and photoproteins as effective reporters, are gaining more and more 
popularity. This is due to availability of the enzymes, their non-toxicity, impressive simplicity 
of the reactions, and high sensitivity of the assay which they provide [1, 2]. The combination 
of luciferase with a biospecific recognition molecule (immunoglobulin, oligonucleotide, 
hapten, etc.) offers a sensitive and selective tool (bioluminescent labels) for molecular binding 
assay. 
Aptamers are single-chain DNA or RNA oligonucleotides (20-80 bases long) with a unique 
spatial structure formed by the local complementary duplexes, stacking interactions, hydrogen 
bonds net etc. The conventional selection procedure provides to aptamers with a high affinity 
to the desired target from randomly synthesized library [3]. Aptamers as biospecific 
recognition molecules successfully compete with antibodies because they are easily 
synthesized chemically, and can be selected for almost any target, including that of low 
molecular weight, toxic and non-immunogenic. Owing to these advantages, aptamers are 
increasingly being used as biospecific elements in a number of biomedical analytical systems 
[4]. The targets for aptamer selection can be not only biochemically pure entities but complex 
biological systems like cultural cells, e.g. at cancer investigations [5-9] and tissues. Recently a 
group of ten DNA aptamers to postoperative lung adenocarcinoma was selected [10]. All of 
them demonstrated high affinity to the tumor tissue elements (mostly cells) and the binding 
absence with healthy lung tissue and blood cells. Fluorescently labeled aptamers from this 
group – LС-17 and LC-18, were successfully applied for detection of blood circulating tumor 
cells in patients with lung adenocarcinoma by confocal fluorescent microscopy [10] and for 
histological examinations of lung adenocarcinoma [11]. The aim of our research was to 
develop the solid-phase assay based on this couple of aptamers (LС-17 and LC-18) as sensing 
elements and the recombinant Ca2+-regulated photoprotein obelin as a high sensitive 
bioluminescent reporter to detect lung tumor elements circulating in blood. The 98 clinical 
blood samples (from patients with lung cancer or other lung diseases and healthy donors) 
were investigated using the assay. The main analytical characteristics of the proposed method 
and its prospects were evaluated. 
 
2. Materials and methods 
The highly purified Ca2+-regulated photoprotein obelin with a unique cysteine residue (Obe 
D12C) was obtained as described previously [12]. Aptamers LC-17, and LC-18 (Fig S1) were 
selected to postoperative lung adenocarcinoma using cell-SELEX technique as described in 
[10]. The aptamers solutions were heated at 95° C for 5 min and cooled for 5 min on ice 
before use. 
Oligonucleotides 5'-CGTGGTTACAGTCAGAGGAG-3'-Bio (olig1) and 5'-
CGTGGTTACAGTCAGAGGAG-3'-(CH2)6-NH2 (olig2) were synthesized by Biosan 
(Russia). 
All other reagents were of highest quality grade. 
Solid-phase bioluminescent assay was carried out using magnetic particles with covalently 
immobilized streptavidin (Promega, USA). 
Blood samples of 56 patients were obtained from the Krasnoyarsk regional clinical oncology 
center named after A.I. Kryzhanovsky. Blood samples of patients were collected prior to 
surgery for tumor resection. After surgery, the diagnosis of lung cancer was histologically 
confirmed for 47 patients; 3 cases were lung metastases of the other cancer types. Together 
these 50 cases formed the experimental group. The control group contained 6 samples from 
patients with the other diagnoses and 42 samples from healthy volunteers.  
The study was approved by the local Ethics Committee of Krasnoyarsk regional clinical 
oncology center named after A.I. Kryzhanovsky. It was carried out in accordance with the 
ethical standards as stated in the Helsinki Declaration. The informed consent was obtained 
from all the patients under study. 
2.1. Blood sample preparation 
Blood samples with anticoagulant (ethylenediaminetetraacetic acid, EDTA) were centrifuged 
at 3000 rpm for 20 min to obtain plasma. Plasma samples were used for analysis within 24 h 
after collection of blood and were not frozen. Before testing, masking yeast RNA (1 ng μL-1) 
was added to the plasma sample and incubated with shaking for 30 min at room temperature. 
2.2. The chemical conjugate obelin-olig2 was synthesized as described earlier [13]. Briefly, 
olig2 was incubated with a 50-fold molar excess of succinimidyl-4-(N-maleimidomethyl)-
cyclohexane-1-carboxylate (SMCC) (Fluka, Switzerland) for 2 h at room temperature in 0.1 
mM NaHCO3, purified by chromatography and then incubated with a 3-fold molar excess of 
ObeD12C in 20 mM, Tris-HCl, pH 7.0, 5 mM EDTA overnight at 4° C. The conjugate was 
purified by anion-exchange chromatography on Mono Q column (GE Healthcare, UK), 
equilibrated with 20 mM Tris-HCl, pH 7.0, 5 mM EDTA in NaCl concentration gradient (0−1 
M). 
2.3. Conjugate obelin-olig2 detection limit 
Serial conjugate dilutions in 20 mM Tris-HCl pH 7.0, 5 mM EDTA, 0.1 mg mL−1 BSA (100 
μL) were placed into microtiter wells and bioluminescence was measured with a Mithras LB 
940 plate luminometer (Berthold, Germany) immediately after the rapid injection of 100 μL of 
CaCl2 solution (0.1 M, in 0.1 M Tris-HCl pH 8.8). The signal was integrated for 5 s. Detection 
limit was calculated as a sample concentration with a signal-to-background ratio of 2 (three 
replicates). 
2.4. Cells suspensions preparation 
The samples of cells suspensions were prepared from 1 g of lung tissue. Cancer material was 
washed with Dulbecco's phosphate-buffered saline (DPBS), minced into small pieces and 
then gently pipetted with DPBS to remove cells clusters and obtain a homogeneous 
suspension. Cell suspension was filtered through 70 μL filters, centrifuged at 3000g for 5 min 
and the cells pellet washed three times with DPBS followed by centrifugation. Final pellet 
was resuspended in 100 mM PBS (phosphate-buffered saline, pH 7.5) and used for the assay. 
2.5. Bioluminescent solid-phase assay 
The 240 µL plasma sample or postoperative lung cells suspension or PBS (control) was 
incubated with equimolar mixture of 60 μL LC-17 aptamer and olig1 (each final 
concentration of 250 nM) in 20 mM Tris-HCl, pH 7.0, 5 mM EDTA, and magnetic particles 
(30 μg per analysis), for 30 min with shaking, at room temperature. After incubation, the 
particles were washed three times with solution of 20 mM Tris-HCl, pH 7.0, 5 mM EDTA 
(hereinafter – the buffer) fixing the particles on the tube wall by magnet and sucking off the 
supernatant. 
The 60 μL LC-18 aptamer (250 nM in 20 mM Tris-HCl, pH 7.0, 5 mM EDTA) was added to 
the particles, incubated and washed in the same way. Next, a conjugate obelin-olig2, was 
added into the tube (1.3 μg mL-1 in 20 mM Tris-HCl, pH 7.0, 5 mM EDTA), incubated and 
washed similarly. 
The particles suspended in 60 μL of the buffer were transferred into the wells of an opaque 
96-well microplate (Costar, USA) and the bioluminescent signal was measured immediately 
after the rapid injection of 100 μL of CaCl2 solution as described above. 
The averaged signal, received from control samples (n=2) was taken as the background and 
subtracted from the ones from working wells. 
2.6. Statistical analysis 
The collected data were statistically analyzed using Statistica software, version 12.0 (StatSoft, 
Russia) and MedCalc Software for Windows, version 18.2.1 (MedCalc Software, Ostend, 
Belgium).  
The bioluminescent signals of sample from patients and controls were compared by Mann-
Whitney U-test and assessed using the area under a receiver operating characteristic (AUC) 
curve. The cut-off value was determined by the optimal Youden’s index (sensitivity + 
specificity -1) and used to calculate sensitivity and specificity. 
The results of the assay obtained for the two groups of patients with different cancer types 
were compared by Mann-Whitney U-test. Those obtained from patients with different cancer 
stages were compared by Kruskal-Wallis test. The p-value <0.05 was considered as 
significant. 
 
3. Results 
3.1. Study design 
In the present research, we developed a solid-phase sandwich type assay of lung cancer 
elements (mostly cells) in plasma based on DNA aptamers LC-17 and LC-18 selected to the 
postoperative lung cancer tissues as biospecific elements and Ca2+-regulated photoprotein 
obelin as a highly sensitive bioluminescent reporter (Fig. 1). LC-17 and LC-18 possess high 
affinity to post operative lung tissue with kd= 14 nM, and 38 nM correspondingly [10], bound 
different ligands and were already successfully applied as reporter for characterization of 
histological structure of lung adenocarcinoma [11]. 
 
Fig. 1. Scheme for the solid-phase bioluminescent assay. 
 
Aptamer molecules are arranged similarly: they include constant fragments at 3' and 5' ends 
(20 n.b. each), whereas their central parts differ in sequences and frequently form spatial 
structures, responsible for target binding. An oligonucleotide complementary to the 5' end of 
both aptamers was synthesized in two variants: the first one contained biotin at the 5' end 
(olig1), the second – amino group connected through hexamethylene spacer (olig2). Olig1 
was immobilized on the magnetic streptavidin-covered microparticles, and the first aptamer 
LC-17 was attached to it due to 5' end complementarity. The resulting microparticle surface 
captured the target due to LC-17 affinity. 
The second aptamer LC-18 forms a sandwich-type structure with the target. The resulting 
complex is detected with the conjugate obelin-olig2, serving as a bioluminescent label. Ca2+-
regulated photoprotein obelin is a stable noncovalent complex of single-chain (22.2 kDa) 
polypeptide and 2-hydroperoxycoelenterasine. Its bioluminescence as a flash of blue light 
(λmax= 480 nm) is triggered by the addition of Ca2+. As far as the protein takes part in the 
reaction directly the dependence of bioluminescence on protein concentration is always linear. 
Figure 2A shows the dependence of olig2-obelin conjugate bioluminescence on its amount. 
The detection limit of the conjugate is 20.8 ± 1.5 amol confirming it as a high sensitive label 
for binding assay. 
 
Fig. 2. (A) Bioluminescence as a function on olig2-obelin conjugate amount. Each point is an 
average ± 1 standard deviation (n = 3). Some error bars are obstructed by the symbols. Signal 
from empty buffer is shown in red. (B) Model assay of two samples prepared from cancer 
(gray columns) and healthy (white column) lung tissues. r.l.u. - relative light units. 
 
To test the approach, model solid-phase microassay of sandwich type was carried out using 
the samples of postoperative cancer and healthy lung tissues as targets (Fig. 2B). The samples 
were prepared as those used for the aptamers’ selex [10]. Bioluminescent signal depends on 
the dilutions of cancer samples whereas the signal from the sample of healthy lung tissue 
remains at a constant low level. 
3.2. Clinical samples analysis 
Totally 98 plasma samples were analyzed by the developed assay. Samples from 56 patients 
(49 men and 7 women aged 34 to 86 years) were collected prior to surgery for tumor 
resection. Note, that proportion of men/women cases of lung cancer in our sampling 
corresponds with the one taking place in Krasnoyarsk region: 78.6 cases per 100 thousand 
males vs 15 per 100 thousand females [14]. Control samples contained 42 healthy in terms of 
lung cancer volunteers (14 men and 28 women aged 20 to 67 years). Diagnosis of lung cancer 
was histologically proved for the 47 patients: adenocarcinoma (22); squamous cell carcinoma 
(23); small cell and glandular squamous cell carcinoma (1 each). Finally, control group 
consisted of 48 samples (42 healthy volunteers plus 6 patients with non-cancer lung diseases). 
The results of the bioluminescent aptamer-based assay in plazma samples from patients with 
lung cancer and control group are shown in Figure 3. Elevated signals levels in lung cancer 
patients were statistically significant (p<0.001). From the receiver-operator curve (ROC) 
analysis, the chosen threshold value as clinical decision limit offers sensitivity of 92% and 
specificity of 88% (Fig. 3A). The area under the ROC curve (AUC) value of 0.928 
distinguishes well between the two groups under investigation (Fig. 3B). 
 
 
Fig. 3. (A) The levels of cancer-associated target in histologically confirmed lung cancer 
patients and control group. Blue circuses present the results of the samples from patients with: 
1,4 –pneumosclerosis; 2 – Hodgkin lymphoma; 3,5 – tuberculosis; 6 – chondroid hamartoma; 
7-9 – lung metastases of other cancer types. (B) The ROC curve analysis for evaluating the 
proposed assay. 
 
Bioluminescent analysis of plazma samples and histological investigation were carried out 
independently. Among the samples under investigation, there were several cases with 
histologically unconfirmed lung cancer, namely: chondroid hamartoma (1), Hodgkin 
lymphoma (1), tuberculosis (2), pneumosclerosis (2), lung metastases of other cancer types 
(3). All these samples were analyzed with the developed bioluminescent assay as well (Fig. 
3A). All the three cases of lung metastases of other cancer types gave undoubtedly positive 
results (Fig. 3A). The case of chondroid hamartoma gave a negative result, whereas the results 
on Hodgkin lymphoma, tuberculosis and pneumosclerosis were doubtful, but the amount of 
all these cases was not enough for interpretation. The possibility exists that the development 
of these non-cancer diseases causes similar targets in blood that are characteristic of lung 
carcinoma as well. This question is of great importance and needs further elucidation. For 
example, as it is described early [15] circulating tumor cells were found in blood of patients 
with chronic obstructive pulmonary disease and in these patients was diagnosed lung 
oncology after 1-4 years. 
In our investigation, there were cases with: the first stage of cancer (cancer is found in the 
lung, but not spread outside the lung) – 10, the second – 12, the third – 18, and the fourth 
(cancer has spread to lung, into the area around the lungs, or to distant organs) – 7. The 
question was whether the proposed method of analysis could detect the different stages of 
cancer? The signals from samples with different stages were compared using Kruskal-Wallis 
test (Fig. 4A). As one may see there were no significant differences between the groups 
(p>0.05). Of note is a good result on the early stage detection: the assay is able to reveal 8 of 
10 cases of the first cancer stage and 11 of 12 cases of the second stage. As to the late cancer 
stages, the assay detected 17 of 18 cases of the third stage and all the cases of the forth one. 
 
Fig. 4. Bioluminescent signals from samples of patients with different stages (A) and type (B) 
of lung cancer. The line indicates the threshold value. Samples 1-6 show the results from the 
cases with histologically unconfirmed cancer lung cancer (see Fig. 3A). Blue line shows the 
threshold value (see Fig. 3A). 
 As we have noted above, the cases of adenocarcinoma (22) and squamous cell carcinoma (23) 
were prevailing in patients. It was found (Fig. 4B) that the developed assay could not 
differentiate the lung cancer type (p>0.05, Mann-Whitney U-test). 
4. Discussion 
Thus, the results of our research demonstrated a good potential of the developed 
bioluminescent assay based on two DNA aptamers with high affinity to lung cancer-
associated targets: it provides differentiation between lung cancer and healthy cases with a 
high sensitivity and specificity. Previously suitability of fluorescently labeled aptamers LC-17 
and LC-18 for the aptahistochemical staining of both tumor tissue and circulating tumor cells 
was shown by G. Zamai and co-authors [11]. To detect stained tissues or cells laser-scanning 
fluorescent microscopy or flow cytometry were applied that were expensive and requires 
highly qualified staff. Besides, these approaches need complex procedure of sample 
preparation. Presented here analytical approach based on the same aptamers affinity and 
bioluminescent reporter high sensitivity looks much simpler and cheaper.  
 Application of the other aptamers from the group selected to lung cancer may help to 
improve the specificity of the analysis aiming to exclude the cases of the other lung diseases. 
It is proposed that aptamers selected to the tissue are able to detect not only circulation of 
tumor cells but cellular debris, as well as cells forming the tumor microenvironment, involved 
into tumorigenesis [16]. That is why we suppose that our method allows detecting not only 
cancer cells, but also the other elements associated with the disease. The composition and 
dynamics of such elements is known to significantly differ in patients even with the same 
diagnosis [17] and therefore the use of a family of aptamers specific to cancer associated 
targets can be promising. Similar approach was developed by Smith and co-authors [18, 19], 
where target cells were detected using a panel of specific aptamers immobilized on the two 
kinds of nanoparticles: one magnetic (to collect and enrich cancer cells) and the fluorescent 
one (to detect the cell using confocal microscope or fluorescent plate reader). 
Design of the method proposed here makes possible application of other aptamers for 
simultaneous detection of several targets as far as it includes a set of the universal connecting 
labeled oligonucleotides to form the analytical complex on the microspheric particles. Since 
all aptamers contain the same technological sequences at the 3 'and 5' ends, the transition to 
multiplex variant of the analysis does not require the development of new labels or any 
changes in the analysis scheme. As opposed to the fluorescent, the bioluminescent signal of 
the obelin reporter is bright (due to high quantum yield of the reaction), with a high signal-to-
noise ratio providing high sensitivity of the target detection. Simple obelin bioluminescence 
triggering and its fast signal in combination with microplate format provide the high 
throughput of the assay. 
Thus, our studies demonstrate the potential of the bioluminescent assay on the base of 
aptamers as sensing elements for lung cancer detection and monitoring as well as future 
research direction. 
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